stockrow
Saturday 7 November 2026
Export BMGL’s income statement to Excel — free account
Basel Medical Group Ltd
BMGL Healthcare Medical Care Facilities
Basel Medical Group Ltd’s revenue for fiscal 2026 (year ended June 2026) was $12.8 million, up 43.9% from fiscal 2025.
5.25
0.06
+1.16%
Follow BMGL
Alert me
| Jun '24 | Jun '25 | Jun '26 | |
|---|---|---|---|
Piotroski F-Score |
— | — | 4 |
P/FCF ratio |
0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | 8.19 | (2.34) |
P/Operating CF |
0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | 0.00 | (1.06) |
EV/FCF |
0.00 | 0.00 | (1.03) |
Quick Ratio |
2.03 | 1.19 | 1.20 |
Current Ratio |
2.26 | 1.23 | 1.23 |
Net Debt/EBITDA |
0.90 | (0.42) | (18.33) |
Debt/Assets |
26.30% | 20.29% | 48.67% |
Debt/Equity |
0.57 | 0.70 | 1.91 |
Asset Turnover |
0.00 | 0.70 | 0.95 |
Operating CF/Net income |
1.21 | 0.36 | 0.91 |
Capex/Depreciation |
(0.26) | (0.51) | (0.70) |
Interest Coverage |
14.65 | (5.67) | (1.72) |
| 0.00% | (202.11%) | (15.90%) | |
| 0.00% | (75.17%) | (4.32%) | |
ROIC |
16.29% | (13.62%) | (3.93%) |
Return on Tangible Assets |
22.92% | (446.95%) | (29.53%) |
Average Days of Receivables |
456.20 | 313.78 | 249.63 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
36.21% | 56.52% | 56.18% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 1.82% |
Graham Net Nets |
0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | — |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% |
Revenue per Share |
5.48 | 5.69 | 8.10 |
Operating CF per Share |
1.37 | (2.18) | (0.34) |
Capex per Share |
0.00 | (0.03) | (0.12) |
Free Cash Flow per Share |
1.36 | (2.21) | (0.46) |
Cash per Share |
1.06 | 1.50 | 0.26 |
Shareholders Equity per Share |
4.12 | 2.44 | 2.22 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
4.12 | 2.44 | 2.22 |
Free Cash Flow |
1.85 | (3.46) | (0.72) |
Working Capital |
6.65 | 1.91 | 1.75 |
Capital Expenditures |
(0.01) | (0.04) | (0.19) |
Net Current Asset Value |
5.48 | 0.89 | (0.87) |
EV/EBIT |
0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.02 |
| Other line items | |||
Depreciation/Fixed assets |
0.87 | 0.39 | 1.24 |
Cash ROIC |
18.12% | (39.06%) | (6.83%) |
Accounts Receivable Turnover |
0.00 | 1.05 | 1.56 |
Accounts Payable Turnover |
0.00 | 0.54 | 0.75 |
Inventory Turnover |
0.00 | 11.38 | 12.93 |
Average Days of Payables |
418.22 | 998.82 | 326.91 |
Days of Inventory on Hand |
11.71 | 54.38 | 21.23 |
Average Receivables |
— | 8.46 | 8.21 |
Average Payables |
— | 3.67 | 4.09 |
Average Inventory |
— | 0.17 | 0.24 |
Average Assets |
— | 12.64 | 13.50 |
Average Common Equity |
— | 4.70 | 3.67 |
Columns are period end dates · fundamentals updated 3 Nov 2026